FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211119384> ?p ?o ?g. }

• W4211119384 endingPage "508" @default.
• W4211119384 startingPage "500" @default.
• W4211119384 abstract "PurposeRandomized controlled trials (RCTs) are the cornerstone of delivering sustained improvements in cancer outcome. To inform radiation therapy research policy and prioritization, we analyze the radiation therapy RCT landscape including comparison with trials of systemic therapies over the same period, with a specific focus on funding and disparities across income settings.Methods and MaterialsThis retrospective cohort study identified all phase 3 RCTs evaluating anticancer therapies published from 2014 to 2017. RCTs were classified according to anticancer modality and country of origin. Descriptive statistics were used to compare key characteristics of radiation therapy RCT studies according to study design characteristics, tumor types evaluated, types of intervention appraised, treatment intent and main funding sources.ResultsThe study cohort included 694 RCTs of which 64 were radiation therapy RCTs (9%) compared with 601 systemic therapy RCTs (87%). Among all radiation therapy RCTs, 47% of them focused on 2 areas of evaluation: (1) combining radiation therapy with systemic agents (25%) and (2) changes in dose fractionation (22%). The most common cancers studied were head and neck (22%), lung (22%), and breast (14%), with cervical cancer trials representing only 3% of the cohort. Among the radiation therapy RCTs, 33% of them met their primary endpoint, and 62% assessed interventions in the curative setting compared with 31% in systemic therapy RCTs. For their country locations, 77% of radiation therapy RCTs took place in high-income countries, 13% in low-and-middle-income countries, and 11% in both high-income and low-and-middle-income countries. For funding, 17% of radiation therapy RCTs received funding from industry compared with 79% of systemic therapy RCTs.ConclusionsThis study highlights the need for greater investment in radiation therapy RCTs and the need to look at the disparities in conducting RCTs globally. The study emphases the urgent need for more capacity building for cancer clinical trials in low-and-middle-income countries and more sustainable funding sources. Randomized controlled trials (RCTs) are the cornerstone of delivering sustained improvements in cancer outcome. To inform radiation therapy research policy and prioritization, we analyze the radiation therapy RCT landscape including comparison with trials of systemic therapies over the same period, with a specific focus on funding and disparities across income settings. This retrospective cohort study identified all phase 3 RCTs evaluating anticancer therapies published from 2014 to 2017. RCTs were classified according to anticancer modality and country of origin. Descriptive statistics were used to compare key characteristics of radiation therapy RCT studies according to study design characteristics, tumor types evaluated, types of intervention appraised, treatment intent and main funding sources. The study cohort included 694 RCTs of which 64 were radiation therapy RCTs (9%) compared with 601 systemic therapy RCTs (87%). Among all radiation therapy RCTs, 47% of them focused on 2 areas of evaluation: (1) combining radiation therapy with systemic agents (25%) and (2) changes in dose fractionation (22%). The most common cancers studied were head and neck (22%), lung (22%), and breast (14%), with cervical cancer trials representing only 3% of the cohort. Among the radiation therapy RCTs, 33% of them met their primary endpoint, and 62% assessed interventions in the curative setting compared with 31% in systemic therapy RCTs. For their country locations, 77% of radiation therapy RCTs took place in high-income countries, 13% in low-and-middle-income countries, and 11% in both high-income and low-and-middle-income countries. For funding, 17% of radiation therapy RCTs received funding from industry compared with 79% of systemic therapy RCTs. This study highlights the need for greater investment in radiation therapy RCTs and the need to look at the disparities in conducting RCTs globally. The study emphases the urgent need for more capacity building for cancer clinical trials in low-and-middle-income countries and more sustainable funding sources." @default.
• W4211119384 created "2022-02-13" @default.
• W4211119384 creator A5010167072 @default.
• W4211119384 creator A5019425529 @default.
• W4211119384 creator A5022864667 @default.
• W4211119384 creator A5025843381 @default.
• W4211119384 creator A5030964546 @default.
• W4211119384 creator A5033279700 @default.
• W4211119384 creator A5033287152 @default.
• W4211119384 creator A5039335155 @default.
• W4211119384 creator A5047081894 @default.
• W4211119384 creator A5053685449 @default.
• W4211119384 creator A5056009334 @default.
• W4211119384 creator A5067669459 @default.
• W4211119384 creator A5089899558 @default.
• W4211119384 date "2022-07-01" @default.
• W4211119384 modified "2023-10-13" @default.
• W4211119384 title "Is Clinical Research Serving the Needs of the Global Cancer Burden? An Analysis of Contemporary Global Radiation Therapy Randomized Controlled Trials" @default.
• W4211119384 cites W1973962628 @default.
• W4211119384 cites W2090708746 @default.
• W4211119384 cites W2127298886 @default.
• W4211119384 cites W2142274267 @default.
• W4211119384 cites W2164437838 @default.
• W4211119384 cites W2311406757 @default.
• W4211119384 cites W2317940379 @default.
• W4211119384 cites W2554147819 @default.
• W4211119384 cites W2560013106 @default.
• W4211119384 cites W2560456746 @default.
• W4211119384 cites W2773604620 @default.
• W4211119384 cites W2792349552 @default.
• W4211119384 cites W2799784802 @default.
• W4211119384 cites W2889646458 @default.
• W4211119384 cites W2912332532 @default.
• W4211119384 cites W2947820602 @default.
• W4211119384 cites W3006019089 @default.
• W4211119384 cites W3048751087 @default.
• W4211119384 cites W3121373553 @default.
• W4211119384 cites W3125743225 @default.
• W4211119384 cites W3128646645 @default.
• W4211119384 doi "https://doi.org/10.1016/j.ijrobp.2022.01.053" @default.
• W4211119384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35151802" @default.
• W4211119384 hasPublicationYear "2022" @default.
• W4211119384 type Work @default.
• W4211119384 citedByCount "14" @default.
• W4211119384 countsByYear W42111193842022 @default.
• W4211119384 countsByYear W42111193842023 @default.
• W4211119384 crossrefType "journal-article" @default.
• W4211119384 hasAuthorship W4211119384A5010167072 @default.
• W4211119384 hasAuthorship W4211119384A5019425529 @default.
• W4211119384 hasAuthorship W4211119384A5022864667 @default.
• W4211119384 hasAuthorship W4211119384A5025843381 @default.
• W4211119384 hasAuthorship W4211119384A5030964546 @default.
• W4211119384 hasAuthorship W4211119384A5033279700 @default.
• W4211119384 hasAuthorship W4211119384A5033287152 @default.
• W4211119384 hasAuthorship W4211119384A5039335155 @default.
• W4211119384 hasAuthorship W4211119384A5047081894 @default.
• W4211119384 hasAuthorship W4211119384A5053685449 @default.
• W4211119384 hasAuthorship W4211119384A5056009334 @default.
• W4211119384 hasAuthorship W4211119384A5067669459 @default.
• W4211119384 hasAuthorship W4211119384A5089899558 @default.
• W4211119384 hasBestOaLocation W42111193841 @default.
• W4211119384 hasConcept C121608353 @default.
• W4211119384 hasConcept C126322002 @default.
• W4211119384 hasConcept C168563851 @default.
• W4211119384 hasConcept C185926286 @default.
• W4211119384 hasConcept C203092338 @default.
• W4211119384 hasConcept C509974204 @default.
• W4211119384 hasConcept C530470458 @default.
• W4211119384 hasConcept C535046627 @default.
• W4211119384 hasConcept C71924100 @default.
• W4211119384 hasConcept C72563966 @default.
• W4211119384 hasConceptScore W4211119384C121608353 @default.
• W4211119384 hasConceptScore W4211119384C126322002 @default.
• W4211119384 hasConceptScore W4211119384C168563851 @default.
• W4211119384 hasConceptScore W4211119384C185926286 @default.
• W4211119384 hasConceptScore W4211119384C203092338 @default.
• W4211119384 hasConceptScore W4211119384C509974204 @default.
• W4211119384 hasConceptScore W4211119384C530470458 @default.
• W4211119384 hasConceptScore W4211119384C535046627 @default.
• W4211119384 hasConceptScore W4211119384C71924100 @default.
• W4211119384 hasConceptScore W4211119384C72563966 @default.
• W4211119384 hasIssue "3" @default.
• W4211119384 hasLocation W42111193841 @default.
• W4211119384 hasLocation W42111193842 @default.
• W4211119384 hasLocation W42111193843 @default.
• W4211119384 hasOpenAccess W4211119384 @default.
• W4211119384 hasPrimaryLocation W42111193841 @default.
• W4211119384 hasRelatedWork W1965214250 @default.
• W4211119384 hasRelatedWork W2056534599 @default.
• W4211119384 hasRelatedWork W2355955825 @default.
• W4211119384 hasRelatedWork W2590004410 @default.
• W4211119384 hasRelatedWork W2894984500 @default.
• W4211119384 hasRelatedWork W3081920103 @default.
• W4211119384 hasRelatedWork W3093538641 @default.
• W4211119384 hasRelatedWork W3173804344 @default.
• W4211119384 hasRelatedWork W4280638132 @default.
• W4211119384 hasRelatedWork W4367834913 @default.
• W4211119384 hasVolume "113" @default.

• next